We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FCNCA:NASDAQFirst Citizens BancShares, Inc. Analysis

Data as of 2026-03-11 - not real-time

$1,912.46

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

First Citizens BancShares (FCNCA) is trading at $1912.46, just below its 20‑day SMA of $1,988.6 but above the 200‑day SMA of $1,950.5, indicating a modestly bullish medium‑term bias. The RSI of 39 points to a near‑oversold condition, while the MACD remains bearish, suggesting short‑term downside pressure yet ample room above the $1,819.7 support level. Valuation metrics are attractive: a trailing P/E of 11.6 versus the industry average of 17.3 and a P/B of 1.11 signal a potential discount, though the DCF‑derived fair value of $1,670.3 implies the market price is modestly premium. The stock’s dividend yield is low at 0.44% with a payout ratio of just 4.8%, underscoring strong dividend sustainability given its $21.4 B cash pile.
Recent material news adds a positive catalyst mix: analysts expect an earnings beat, the CEO’s appointment to the Federal Advisory Council enhances regulatory credibility, and the firm is actively scouting M&A opportunities, including a rumored pursuit of KeyCorp. However, an investor‑focused lawsuit investigation introduces a headwind. Overall, the combination of undervalued multiples, solid cash generation, and strategic upside potential supports a cautiously optimistic outlook.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Near‑oversold RSI and price cushion above support
  • Anticipated earnings beat
  • Low payout ratio preserving cash

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Attractive valuation relative to industry peers
  • Strong operating margins and ROE
  • Potential M&A transactions expanding earnings base

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • Sustainable dividend policy with ample cash reserves
  • CEO’s Federal Advisory Council role reducing regulatory uncertainty
  • Stable regional banking franchise with diversified product lines

Key Metrics & Analysis

Financial Health

Revenue Growth6.20%
Profit Margin24.41%
P/E Ratio11.6
ROE9.92%
ROA0.97%
P/B Ratio1.1
Op. Cash Flow$2.9B
Industry P/E17.3

Technical Analysis

TrendNeutral
RSI39.3
Support$1,819.68
Resistance$2,197.03
MA 20$1,988.63
MA 50$2,072.15
MA 200$1,950.48
MACDBearish
VolumeStable
Fear & Greed Index76.91

Valuation

Fair Value$1,670.27
Target Price$2,295.07
Upside/Downside20.01%
GradeFair
TypeValue
Dividend Yield0.44%

Risk Assessment

Beta1.14
Volatility33.92%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.